Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of Testogel® 50mg/5g gel
administered once daily (QD, morning dosing) compared to placebo administered once daily (QD,
morning dosing), for 3 months, in hypogonadal men with testosterone deficiency being
confirmed by clinical features and biochemical tests. For men with hypogonadism, treatment
aims to restore testosterone levels to normal physiological range.